A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

NCT00002185 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma, Kaposi
HIV Infections

Interventions

DRUG: Nelfinavir mesylate

Sponsor

Agouron Pharmaceuticals